SCHEDULE: Velan Capital Boosts Stake in Jasper Therapeutics Post-Merger

Velan Capital Investment Management LP and affiliated entities have increased their beneficial ownership in Jasper Therapeutics, Inc. to 9.88% following the company's acquisition of Kira Pharmaceuticals.

Summary

• Velan Capital Investment Management LP and its affiliates have disclosed an increased beneficial ownership stake in Jasper Therapeutics, Inc. to 9.88% of the outstanding shares.
• This filing is an amendment to a Schedule 13D, indicating a change in beneficial ownership.
• The increase in stake follows Jasper Therapeutics' acquisition of Kira Pharmaceuticals on July 16, 2026, through a merger agreement.
• As a result of the merger, Vishal Kapoor resigned from the Board of Directors, effective immediately after the merger's completion.
• The total number of outstanding shares is now reported as 33,204,811, including shares issued post-merger.
• Velan Capital Master Fund LP holds 3,021,915 shares (8.9%), Velan Horizon Fund LP holds 82,304 shares (0.2%), and Avego Healthcare Capital, L.P. holds 245,328 shares (0.7%).
• The aggregate beneficial ownership for Velan Capital Investment Management LP and its related entities is 3,349,547 shares, representing 9.88% of the outstanding stock.
• Vishal Kapoor directly beneficially owns 35,013 shares, including shares from stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily a disclosure of ownership changes and a corporate event (merger), rather than an indicator of immediate performance or strategic shifts beyond the disclosed acquisition.

Positives

• Velan Capital has increased its investment in Jasper Therapeutics, signaling confidence in the company's future prospects.
• The acquisition of Kira Pharmaceuticals by Jasper Therapeutics represents a significant strategic move for the company.
• The total beneficial ownership of 9.88% by Velan Capital and its affiliates indicates a substantial stake, potentially influencing corporate strategy.

Negatives

• Vishal Kapoor resigned from the Board of Directors following the merger, which could be seen as a change in leadership dynamics.
• The beneficial ownership is subject to a 9.99% beneficial ownership blocker provision, limiting further immediate increases without potential implications.

Risks

• Potential for increased scrutiny from regulatory bodies due to significant ownership stakes.
• The integration of Kira Pharmaceuticals post-merger presents operational and strategic risks.
• The Ownership Limitation may restrict further investment by reporting persons.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from management regarding future financial performance. The primary focus is on the disclosure of beneficial ownership changes and the recent merger.

Management Comments

• Vishal Kapoor resigned from the Board of Directors, effective immediately after the Effective Time of the Merger Agreement.
• The reporting persons disclaim beneficial ownership of securities they do not directly own.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing reflects a significant shift in beneficial ownership for Jasper Therapeutics following its acquisition of Kira Pharmaceuticals. Such filings are common after major corporate events like mergers, as investment firms adjust their holdings and reporting obligations. The increased stake by Velan Capital suggests a strategic interest in the combined entity's future, particularly within the biotechnology sector.

Comparison to Industry Standards

• The 9.88% ownership stake by Velan Capital is a substantial position, often indicative of an activist investor or a significant strategic holder in the biotechnology sector.
• Companies in the biotechnology sector frequently undergo mergers and acquisitions, with post-deal ownership adjustments being a standard occurrence.
• The disclosure of shares underlying warrants and options is a common practice in the industry to provide a fuller picture of potential ownership.

Management Changes

Stakeholder Impact

• Shareholders: Increased concentration of ownership by Velan Capital may influence future corporate decisions and potentially impact share price volatility.
• Management: The resignation of Vishal Kapoor from the Board of Directors signifies a change in governance structure post-merger.
• Creditors: No direct impact mentioned, but long-term performance of the merged entity will affect financial obligations.

Next Steps

• Monitoring the integration of Kira Pharmaceuticals into Jasper Therapeutics.
• Observing any future actions or statements from Velan Capital regarding their stake.
• Tracking the performance of the combined entity post-merger.

Key Dates

Recommendation

The filing primarily discloses an increase in beneficial ownership by Velan Capital following a merger. While the acquisition of Kira Pharmaceuticals is a significant event, the filing itself does not provide performance metrics or forward-looking guidance that would warrant a strong buy or sell recommendation. A 'hold' recommendation is appropriate pending further information on the integration and performance of the combined entity.

Keywords

Jasper Therapeutics, Schedule 13D, Velan Capital, Kira Pharmaceuticals, Merger, Beneficial Ownership, Stock, SEC Filing